High-rolling investors have positioned themselves bearish on Cytokinetics (NASDAQ:CYTK), and it’s important for retail traders to take note.\This activity came to our attention today through Benzinga’s tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in CYTK often signals that someone has privileged information. Today, Benzinga’s options scanner spotted 9 options trades for Cytokinetics. This is not a typical pattern. The sentiment among these major traders is split, with 22% bullish and 66% bearish. Among all the options…